| [1] |
国家卫生健康委疾病预防控制局.中国居民营养与慢性病状况报告（2020年）[M].北京：人民卫生出版社，2022：73-76.
|
| [2] |
海峡两岸医药卫生交流协会老年医学专业委员会.≥75岁老年患者血脂异常管理的专家共识[J].中国心血管杂志，2020，25（3）：201-209.
|
| [3] |
Song R, Hu M, Qin X, et al. The roles of lipid metabolism in the pathogenesis of chronic diseases in the elderly[J]. Nutrients, 2023, 15(15):3433-3450.
|
| [4] |
Ballantyne CM, Varughese MG, Abushamat LA. Lipid-lowering therapy in the elderly: Are current guidelines a sign of ageism in medical care?[J]. J Am Coll Cardiol, 2023, 81(14):1350-1352.
|
| [5] |
Ference BA, Braunwald E, Catapano AL. The LDL cumulative exposure hypothesis: Evidence and practical applications[J]. Nat Rev Cardiol, 2024, 21(10):701-716.
|
| [6] |
Chen X, Zhao X, Fei H, et al. Combined association of triglyceride-glucose index and the atherogenic index of plasma with the incidence of cardiovascular diseases among middle-aged and older population[J]. Cardiovasc Diabetol, 2025, 25(1):19.
|
| [7] |
Qian T, Sheng X, Shen P, et al. Mets-IR as a predictor of cardiovascular events in the middle-aged and elderly population and mediator role of blood lipids[J]. Front Endocrinol (Lausanne), 2023, 14:1224967.
|
| [8] |
Hang B, Wang Y. Interplay between gut microbiota and intestinal lipid metabolism:mechanisms and implications[J]. J Zhejiang Univ Sci B, 2025, 26(10):961-971.
|
| [9] |
Xiao Y, Yang M, Cai M, et al. EGCG and taurine synergistically ameliorate lipid metabolism disorder by modulating gut microbiota and PPARalpha/FAS signaling pathway[J]. Nutrients, 2025, 17(16):2595.
|
| [10] |
Xu D, Feng M, Chu Y, et al. The prebiotic effects of oats on blood lipids, gut microbiota, and short-chain fatty acids in mildly hypercholesterolemic subjects compared with rice: A randomized, controlled trial[J]. Front Immunol, 2021, 9(12):787-797.
|
| [11] |
You M, Zhou L, Wu F, et al. Probiotics for the treatment of hyperlipidemia: Focus on gut-liver axis and lipid metabolism[J]. Pharmacol Res, 2025, 214:107694.
|
| [12] |
中国血脂管理指南修订联合专家委员会.中国血脂管理指南（2023年）[J].中华心血管病杂志，2023 ，51（3）：221-255.
|
| [13] |
Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 focused update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias[J]. Eur Heart J, 2025, 46(42):4359-4378.
|
| [14] |
刘梅林，张雨濛，付志方，等.老年人血脂异常管理中国专家共识[J].中华内科杂志，2022，61（10）：1095-1118.
|
| [15] |
Lee SH, Lee YJ, Heo JH, et al. Combination moderate-intensity statin and ezetimibe therapy for elderly patients with atherosclerosis[J]. J Am Coll Cardiol, 2023, 81(14):1339-1349.
|
| [16] |
Huh J, Kim H. Naturally occurring PCSK9 inhibitors: An updated review[J]. Molecules, 2025, 30(17):3582-3600.
|
| [17] |
Khan SU, Yedlapati SH, Lone AN, et al. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: A systematic review and network meta-analysis[J]. BMJ, 2022, 377:e069116.
|
| [18] |
黄进宇.2024年欧洲心脏病学会血脂热点速递[J].心电与循环，2025，44（2）：113-117.
|
| [19] |
Wright RS, Raal FJ, Koenig W, et al. Inclisiran administration potently and durably lowers LDL-C over an ex tended-term follow-up: The ORION-8 trial[J]. Cardiovasc Res, 2024, 120(12):1400-1410.
|
| [20] |
Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: The ORION-11 trial[J]. Eur Heart J, 2022, 43(48):5047-5057.
|
| [21] |
Leiter LA, Raal FJ, Schwartz GG, et al. Inclisiran in individuals with diabetes or obesity: Post hoc pooled an alyses of the ORION-9, ORION-10 and ORION-11 phase 3 randomized trials[J]. Diabetes Obes Metab, 2024, 26(8):3223-3237.
|
| [22] |
Huo Y, Lesogor A, Lee CW, et al. Efficacy and safety of inclisiran in Asian patients: Results from ORIO N-18[J]. JACC Asia, 2023, 4(2):123-134.
|
| [23] |
Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: One-year follow-up of the ORION-1 randomized clinical trial[J]. JAMA Cardiol, 2019, 4(11):1067-1075.
|
| [24] |
黄燕莹，王京丽，曾平.英克司兰治疗高龄颈动脉斑块患者1例[J].现代医学与健康研究电子杂志，2024，8（16）：23-27.
|
| [25] |
Reyes-Soffer G, Ginsberg HN, Berglund L, et al. American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein (a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American Heart Association[J]. Arterioscler Thromb Vasc Biol, 2022, 42(1): e48-e60.
|
| [26] |
Madsen CM, Kamstrup PR, Langsted A, et al. Lipoprotein (a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: A population-based study[J]. Arterioscler Thromb Vasc Biol, 2020, 40(1):255-266.
|
| [27] |
Cho L, Nicholls SJ, Nordestgaard BG, et al. Design and rationale of Lp(a)HORIZON trial: Assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)[J]. Am Heart J, 2025, 287:1-9.
|
| [28] |
O'Donoghue ML, Rosenson RS, López JAG, et al. The off-treatment effects of olpasiran on lipoprotein(a) lowering: OCEAN(a)-DOSE extension period results[J]. J Am Coll Cardiol, 2024, 84(9):790-797.
|
| [29] |
Xie X, Shi X, Zhang Y, et al. Angiopoietin-like 3 antibody therapy in patients with suboptimally controlled hyperlipidemia: A phase 2 study[J]. J Am Coll Cardiol, 2025, 85(19):1821-1835.
|
| [30] |
Ballantyne CM, Banka P, Mendez G, et al. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616[J]. J Am Coll Cardiol, 2023, 81(16):1553-1564.
|
| [31] |
Hooper AJ, Tang XL, Burnett JR. VERVE-101, a CRISPR base-editing therapy designed to permanently inact ivate hepatic PCSK9 and reduce LDL-cholesterol[J]. Expert Opin Investig Drugs, 2024, 33(8):753-756.
|
| [32] |
Gouni-Berthold I, Schwarz J, Berthold HK. Updates in drug treatment of severe hypertriglyceridemia[J]. Curr Atheroscler Rep, 2023, 25(10):701-709.
|
| [33] |
Bittner V, Linnebur SA, Dixon DL, et al. Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An expert clinical consensus from the national lipid association and the American geriatrics society[J]. J Am Geriatr Soc, 2025, 73(6):1674-1696.
|
| [34] |
李建军.《2025ESC/EAS关于2019年血脂管理指南重点更新》解读[J].临床心血管病杂志，2025，41（10）：755-756.
|
| [35] |
Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An expert clinical consensus from the national lipid association[J]. J Clin Lipidol, 2024, 18(5):e647-e663.
|
| [36] |
Tsimikas S, Bittner V. Particle number and characteristics of lipoprotein(a), LDL, and apoB: Perspectives on contributions to ASCVD[J]. J Am Coll Cardiol, 2024, 83(3):396-400.
|